Developing Gene Therapies for
Rare Ocular Diseases
TeamedOn International, Inc. (TeamedOn) is advancing gene therapies for rare diseases and currently focused on ophthalmic indications. We are developing innovative medicine to treat inherited retinal disorders (IRDs) and other eye diseases with significant unmet medical need. In addition to our internal R&D programs, we are also seeking partners for collaboration or co-development. Our goal is to restore sight and prevent vision loss for patients all around the world. TeamedOn is venture funded and located in Rockville, MD.
Over the past 30 years, gene therapy has been developed as a powerful treatment modality for IRDs, with over 100 clinical trials having been conducted in patients.
Luxturna, an adeno-associated viral vector carrying the RPE65 gene for the treatment of type 2 Leber congenital amaurosis, has been approved by the US FDA as the first gene therapy product for IRDs.
While promising results have also been obtained in clinical studies for choroideremia, X-linked retinitis pigmentosa, and Leber’s hereditary optic neuropathy, no significant improvement has been reported in clinical studies of X-linked retinoschisis and Stargardt disease.
We are developing gene therapies for rare ocular diseases with significant unmet medical need.
